OpiniãoThis second edition of the WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment was prepared by Avinash Kanchar and Saskia den Boon, with inputs from Dennis Falzon and Matteo Zignol and under the overall direction of Tereza Kasaeva, Director, WHO Global Tuberculosis Programme.
The World Health Organization (WHO) thanks the Guideline Development Groups, the External Review Groups, the WHO Guideline Steering Groups and other experts involved since 2020 in production of the WHO consolidated guidelines on tuberculosis. Module 1: Prevention – tuberculosis preventive treatment, with which this handbook is aligned.
WHO also acknowledges the following contributions:
Tiziana Masini (WHO Global Tuberculosis Programme) and the Technical Advisory Group on dosing of TB medicines for adults and children for advice on the dosing of TPT regimens in section 5.
Peter Kerndt and Sevim Ahmedov (US Agency for International Development, Washington DC: United States of America [USA]), provided the contents of Box 2 as well as other information on contact evaluation for section 2.
Anthony D. Harries (International Union against Tuberculosis and Lung Disease, France) for information from the 7–1-7 project for section 2.
Ethel Leonor Noia Maciel (Ministry of Health, Brazil) as well as Tiemi Arakawa, Luiz Henrique Arroyo, Fernanda Dockhorn Costa Johansen, Nicole Menezes de Souza, Daniele Gomes dell Orti, Maria do Socorro Nantua Evangelista, Luiza Ohana Harada, and Daniele Maria Pelissari (National TB Programme, Ministry of Health, Brazil) for contributing country best practice and experience in skill transfer for prescribing TPT in section 5.
Kleydson Andrade (WHO Brazil), Lastone Chitembo (WHO Zambia), Maria Regina Christian (WHO Indonesia), Serongkea Deng (WHO Cambodia), Razia Fatima (Ministry of Health, Pakistan) and Laeeq Ahmad Khawaja (WHO Pakistan) and Nazis Arefin Saki (WHO Bangladesh), Fernanda Dockhorn Costa Johansen and Daniele Maria Pelissari (National TB Programme, Ministry of Health, Brazil) and Quang Hieu Vu (WHO Viet Nam) for providing country examples for section 5.
Ryo Miyakawa, Rada Savic, Maureen Shin and Belén Perez Solans (University of California San Francisco, San Francisco, USA) for preparing the report on pharmacokinetics modelling and simulation of 6 months of daily levofloxacin (6Lfx) in Web Annex A.
Anneke C. Hesseling and Louvina van der Laan (Stellenbosch University, South Africa), Paolo Denti, Lufina Tsirizani Galileya and Roeland Wasmann (University of Cape Town, South Africa) and Rosanna Boyd (Centers for Disease Control and Prevention (CDC), USA) for preparing the report on pharmacokinetics modelling and simulation of 3 months of weekly rifapentine and isoniazid (3HP) in Web Annex A.
Anurag Bhargava (Yenepoya Medical College, India) and Gavin Churchyard and Makaita Gombe (The Aurum Institute, South Africa) for general contributions to the revision of the handbook.
Production of this handbook was funded by a grant to WHO from the United States Agency for International Development.